Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Hematide maintenance therapy for anemia in chronic kidney disease
2006-003846-41Phase 2Terminated
- Sponsor
- Affymax, Inc.
- Start
- Mar 2008
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peginesatide in anaemia and chronic kidney disease (CKD), sponsored by Affymax, Inc. Primary endpoint: Incidence of adverse events. Started Mar 2008; status: terminated.
02
Drugs
peginesatide
03
Conditions
anaemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2006-003846-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003846-41.